As part of the firm's global matrix, members of the global Healthcare, Life Sciences & Chemicals sector team specialise both in specific subsectors and the relevant practice areas to pool our collective resources and experience to benefit our clients.
Clifford Chance's deep understanding of the healthcare industry is integral to our ability to offer the highest quality advice and solutions wherever we operate. We focus on industry sectors so that we can provide you with:
- access to our combined knowledge, expertise and experience by sector
- lawyers who know the risks and challenges within your industry and who proactively bring insights to you.
Our sector approach ensures that our lawyers truly understand the healthcare industry with its regulatory and commercial challenges. At the same time it avoids the build-up of silos between different areas of laws so that we are able to deliver to our clients commercially sound and legally robust solutions focused to their business objectives.
Having cultivated an expertise in the healthcare and life sciences industry over two decades and having worked with many of the world's leading and emerging pharmaceutical, chemicals, medical device and health care services companies, we know the importance of anticipating regulatory and contractual issues in the context of corporate investment, finance, competition, strategy and operations.
Established in the early 1990s, the Global Healthcare and Life Sciences sector team consists of more than 140 dedicated lawyers in 30 centres including Belgium, China, France, Germany, Italy, the Netherlands, Poland, Russia, Spain, United Arab Emirates, the United Kingdom and the United States.
- Advised Takeda GmbH (formerly: Nycomed GmbH) in connection with the sale of its self-medication business (OTC) for the German market to DR.KADE Pharmazeutische Fabrik. DR. KADE, well known for its brands Posterisan and KadeFungin, acquires amongst others brands like Faktu, Sanostol, Riopan and Buer Lecithin
- Advised Pfizer on the sale of its Nutrition business to Nestle. Pfizer’s Nutrition business sells speciality infant and toddler formulas, follow-on formulas, maternal and adult nutrition products and recorded revenues of approximately US$2.1 billion in 2011, an increase of 15% compared with 2010. Pfizer acquired the business as part of its US$68 billion purchase of Wyeth in 2009, on which Clifford Chance also advised
- Advised an Abu Dhabi government delivery agency on a joint venture in the healthcare sector